Xenetic Biosciences Inc Stock Nasdaq
Equities
US9840152063
Biotechnology & Medical Research
Sales 2024 * | 2.13M 2.67M | Sales 2025 * | 1.42M 1.78M | Capitalization | 4.77M 5.97M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.01M | Net income 2025 * | -8M -10.01M | EV / Sales 2024 * | 2.24 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.36 x |
P/E ratio 2024 * |
-1.12
x | P/E ratio 2025 * |
-4.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.81% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 17-04-02 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 14-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 17-08-13 |
1st Jan change | Capi. | |
---|---|---|
-2.16% | 104B | |
+1.75% | 97.42B | |
+0.79% | 22.2B | |
-17.72% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-16.46% | 15.06B | |
+3.67% | 13.98B | |
+34.32% | 11.66B |